3-Methoxyphenethylamine

3-Methoxyphenethylamine
Clinical data
Other names	3-MPEA; meta-Methoxyphenethylamine; m-Methoxyphenethylamine; EA-1302; NSC-124706
ATC code	None;
Identifiers
	IUPAC name 2-(3-methoxyphenyl)ethanamine;
CAS Number	2039-67-0;
PubChem CID	74866;
ChemSpider	67430;
UNII	7WX5W6GM6F;
ChEMBL	ChEMBL316698;
CompTox Dashboard (EPA)	DTXSID10174327 ;
ECHA InfoCard	100.016.381
Chemical and physical data
Formula	C9H13NO
Molar mass	151.209 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC=CC(=C1)CCN;
	InChI InChI=1S/C9H13NO/c1-11-9-4-2-3-8(7-9)5-6-10/h2-4,7H,5-6,10H2,1H3; Key:WJBMRZAHTUFBGE-UHFFFAOYSA-N;

3-Methoxyphenethylamine (3-MPEA) is a drug of the phenethylamine family. It is one of the methoxyphenethylamine positional isomers.

The drug showed very low affinity for the serotonin receptors in the rat stomach fundus strip (A₂ = 1,290 nM). 3-MPEA is a low-potency partial agonist of the human trace amine-associated receptor 1 (TAAR1) (EC₅₀Tooltip half-maximal effective concentration = 1,444 nM; E_maxTooltip maximal efficacy = 73%). The effects of 3-MPEA in humans have not been reported and are unknown.

3-MPEA was first described in the scientific literature by at least 1943. It was studied at Edgewood Arsenal and received the code name EA-1302. The drug was included as an entry in Alexander Shulgin's 2011 book The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds.